At least 4 license deals for 5 indications with DEP® SN38 and DEP®Cabazitaxel
[FONT=Poppins, sans-serif]The company has stated licenses in different indications for both cancer drugs in multiple jurisdictions. At this stage there is no plan for a master license
[/FONT]
DEP®SN38
One new indication for Platinum-resistant/refractory ovarian cancer
One current indication (irinotecan) for Advanced colorectal cancer
DEP®Cabazitaxel
Advanced prostate cancer (current indication)
Platinum-resistant ovarian cancer (new indication)
Advanced gastro-oesophageal cancer (new indication)
I would like to wish all readers a wonderful new year
Over the last months my input has been on discussing Starpharma
I have been baited multiple times by multiple posters and decided not to respond
I hope we can improve in 2025 by not discussing the poster and talk about Starpharma going forward
This way I genuinely believe there will be more interest and therefore more interaction in a positiv manner on the hotcopper forum
Look forward to a very good year not only for those suffering from cancer but us shareholders
Happy new year
At least 4 license deals for 5 indications with DEP® SN38 and...
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
12.5¢ |
Change
0.000(0.00%) |
Mkt cap ! $52.27M | |||
| Open | High | Low | Value | Volume |
| 0.0¢ | 0.0¢ | 0.0¢ | $0 | 0 |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 4443 | 12.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 12.5¢ | 78007 | 1 |
View Market Depth
| Last trade - 10.00am 11/09/2025 (20 minute delay) ? |
| SPL (ASX) Chart |
Day chart unavailable